COVID-19 has continued to alarm public health, and although several therapeutics and vaccines have been developed, the development of effective vaccines or antibodies is challenging due to mutations in the surface of the spike protein in the SARS-CoV-2 virus.
Syndax Pharmaceuticals Inc. has disclosed extended purine tricyclic and bicyclic nucleosides as prodrugs reported to be useful for the treatment of viral infections.
Arrepath Inc. has disclosed UDP-2,3-diacylglucosamine hydrolase (LpxH; bacterial) inhibitors reported to be useful for the treatment of gram-negative bacterial infections.
Hepatitis B virus (HBV) infection is associated with liver diseases, including chronic hepatitis, which notably increases the risk of cirrhosis and hepatocellular carcinoma (HCC) development. Although some of the current treatment strategies promote virological suppression, they are insufficient to halt HCC development.
An Institut Pasteur team has developed an original vaccine platform known as MOPEVAC, that will strengthen the organization’s pandemic preparedness initiatives, with the platform’s first vaccine candidate, which targets Lassa fever, set to enter the clinic.
The ability of influenza virus to rapidly undergo antigenic shift to evade immunity raises the need for effective influenza antivirals with a broad spectrum. In a recent Nature Microbiology article, Cidara Therapeutics Inc. provided preclinical data for their drug-Fc conjugate compound CD-388, which has the potential to be a robust therapeutic option for the universal prevention of both seasonal and pandemic influenza.
The University of Hong Kong has patented RNA polymerase β subunit/RNA polymerase sigma factor RpoD (bacterial) interaction inhibitors reported to be useful for the treatment of gram-positive bacterial infections.
rietis Corp. and St. Jude Children’s Research Hospital Inc. have jointly patented compounds acting as caseinolytic protease P (ClpP) (bacterial) activators and RNA polymerase (bacterial) inhibitors and their conjugates with rifamycin analogues reported to be useful for the treatment of gram-positive bacterial infection.
Decoy Therapeutics Inc. has announced that a series of antiviral drug candidates previously designed by its Imp3act platform to be broadly effective against viruses of the paramyxoviridae family have also shown promising in silico activity against measles and Nipah viruses. The candidates were previously shown to be active in vitro against respiratory syncytial virus and human parainfluenza virus 3.
Writing in Cell Reports, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and collaborators have presented a multifaceted analysis and structure-function study of a panel of human monoclonal antibodies (hmAbs) targeting AMA1 elicited by natural Plasmodium falciparum infection in a malaria-endemic region in Mali.
RSS
